June 2021

breaking news

HIV-1 and TB coinfection skews the SARS-CoV-2 T cell response

HIV-1 and TB co-infection skews the SARS-CoV-2 T cell response. Riou et al, results reinforce the crucial role of SARS-CoV-2-specific T cells in COVID-19 disease development and support the concept…

Bonamy HoltakJune 30, 2021

breaking news

WNT7A: The new marker for resting T cells

Barreto-Vargas, et al., evaluated the WNT7A expression in different subpopulations of peripheral blood mononuclear cells (PBMCS). The data indicates that WNT7A regulates cell proliferation and might act as a new…

Bonamy HoltakJune 28, 2021

breaking news

Does serial administration of HIV-specific VRC01 bnAbs prevent HIV acquisition?

Researchers are investigating alternative strategies to life-long anti-retroviral treatment. An example of such a study, is the antibody (Ab)-mediated protection proof-of-concept trial that tested whether HIV-specific broadly neutralising Ab VRC01…

ChelekaJune 25, 2021

breaking news

An update on the Shock and kill HIV cure strategy

In a recent study, Lu and colleagues investigated whether reactivation of individual latent cells occurs stochastically in response to LRAs or is a deterministic outcome of an underlying cell state.…

ChelekaJune 23, 2021

breaking news

IUIS-Immunopaedia-Frontiers Webinar: Clinical representation of hyperinflammation

Fabrizio De Benedetti gave examples of clinical presentations and laboratory features of hyper-inflammation with a focus on hemophagocytic lymphohistiocytosis (HLH) and macrophage activation syndrome (MAS).

ChelekaJune 18, 2021

breaking news

IUIS-Immunopaedia-Frontiers webinar: In-depth characterisation of immune cells in Ebola virus.

Anita McElroy describes the cellular immune landscape that occurs following Ebola virus infection and will correlate these findings with key features of Ebola virus disease.

ChelekaJune 17, 2021

breaking news

BCG reduces all-cause infectious diseases in the first 6 weeks of life in infants!

Non-specific effects of BCG vaccine have generated a lot of interest with researchers proposing that it likely protects against respiratory viruses like the SARS-CoV-2 virus. Though this is still under…

ChelekaJune 11, 2021

breaking news

IUIS-Immunopaedia-Frontiers webinar: Getting to the “bottom” of arthritis

In a recent IUIS-Immunopaedia-Frontiers in Immunology webinar, Claudia Mauri discussed how microbial products induce B-regs and their relevance for arthritis pathology. Murine models of arthritis have demonstrated that pathology is…

ChelekaJune 9, 2021

breaking news

Immuno-Colombia: Overview of immunotherapy

Professor Rothlin began by giving a brief history of cancer immunotherapy, starting with the first documented description of the tumour immune infiltrate by Virchow in 1863. She then highlighted the…

ChelekaJune 3, 2021

breaking news

Immuno-Colombia: Therapeutic cancer vaccines

Prof. Olivera Finn from the University of Pittsburgh gave an informative talk on therapeutic cancer vaccines. She pointed out that it is only as recent as the 1980s that scientists…

ChelekaJune 2, 2021

HIV-1 and TB coinfection skews the SARS-CoV-2 T cell response

WNT7A: The new marker for resting T cells

Does serial administration of HIV-specific VRC01 bnAbs prevent HIV acquisition?

An update on the Shock and kill HIV cure strategy

IUIS-Immunopaedia-Frontiers Webinar: Clinical representation of hyperinflammation

IUIS-Immunopaedia-Frontiers webinar: In-depth characterisation of immune cells in Ebola virus.

BCG reduces all-cause infectious diseases in the first 6 weeks of life in infants!

IUIS-Immunopaedia-Frontiers webinar: Getting to the “bottom” of arthritis

Immuno-Colombia: Overview of immunotherapy

Immuno-Colombia: Therapeutic cancer vaccines

Advancing Global Online Immunology Education for 20 years

Join our Newsletter

Advancing Global Immunology Education